Qiagen N.V. (QGEN)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 49.19 |
| Open | 49.28 |
| Bid | 49.22 x 800 |
| Ask | 74.05 x 800 |
| Day's range | 49.27 - 49.74 |
| 52-week range | 40.38 - 56.18 |
| Volume | |
| Avg. volume | 1,150,875 |
| Market cap | 11.219B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 24.76 |
| EPS (TTM) | 1.99 |
| Earnings date | 06 Feb 2023 - 10 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 53.00 |
- Zacks
QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification
QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.
- Zacks
3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio
Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.
- Business Wire
QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance
HILDEN, Germany & GERMANTOWN, Maryland, November 21, 2022--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the monkeypox (MPXV) test for its NeuMoDx automated PCR platform to strengthen surveillance and research into the current outbreak in non-endemic regions that has infected tens of thousands of people all over the world since first being identified in May 2022.
© 2022 Yahoo. All rights reserved.
